Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB 1 genetic polymorphisms and interaction with clarithromycin-Reference-Cited by-同舟云学术

Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB 1 genetic polymorphisms and interaction with clarithromycin

Published:2017-02 Issue:2 Volume:15 Page:273-283
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Gouin‐Thibault I.¹²³,Delavenne X.⁴⁵,Blanchard A.²⁶⁷,Siguret V.¹²⁸,Salem J. E.⁹¹⁰¹¹,Narjoz C.¹²¹³,Gaussem P.¹²¹⁴,Beaune P.²¹²¹³,Funck‐Brentano C.⁹¹⁰¹¹,Azizi M.²⁶⁷¹⁵,Mismetti P.⁵¹⁶¹⁷,Loriot M. A.²¹²¹³

Affiliation:

1. INSERM UMR_S1140 Faculté de Pharmacie Paris France

2. Sorbonne Paris Cité Université Paris Descartes Paris France

3. Laboratoire d'Hématologie Biologique Centre Hospitalier Universitaire Pontchaillou Rennes France

4. Laboratoire de Pharmacologie‐Toxicologie Centre Hospitalier Universitaire de Saint‐Etienne Saint‐Etienne France

5. Groupe de Recherche sur la Thrombose Université Jean Monnet Saint‐Etienne France

6. Hôpital Européen Georges Pompidou Centre d'Investigation Clinique Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France

7. INSERM CIC‐1418 Paris France

8. Hôpital Lariboisière Service d'Hématologie Biologique Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France

9. Département de Pharmacologie Hôpital Pitié‐Salpêtrière Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France

10. INSERM CIC‐1421 and Institut de Cardiométabolisme et Nutrition (ICAN) UMR ICAN_1166 Paris France

11. Sorbonne Universités UPMC Université Paris 6 Paris France

12. INSERM UMR_S1147 Centre Universitaire des Saints‐Pères Paris France

13. Hôpital Européen Georges Pompidou Service de Biochimie Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France

14. Hôpital Européen Georges Pompidou Service d'Hématologie Biologique Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France

15. Hôpital Européen Georges Pompidou Unité d'Hypertension Artérielle Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France

16. Service de Médecine Vasculaire et Thérapeutique Centre Hospitalier Universitaire de Saint Etienne Saint Etienne France

17. Unité de Recherche Clinique, Innovation, Pharmacologie Centre Hospitalier Universitaire de Saint Etienne Saint Etienne France

Funder

Assistance Publique des Hôpitaux de Paris

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.13577

Reference43 articles.

1. New Antithrombotic Drugs

2. Pharmacology and mechanisms of action of new oral anticoagulants

3. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics

4. Dose tailoring of dabigatran etexilate: obvious or excessive?

5. Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An accurate haplotyping method using multiplex pyrosequencing with AS-PCR to detect ABCB1 haplotypes associated with rivaroxaban-derived hemorrhagic events;Talanta;2025-01

2. The use of reduced DOAC doses in atrial fibrillation patients does not always lead to good anticoagulation levels and avoid adverse events;International Journal of Cardiology;2024-12

3. Full-dose rivaroxaban in patients with a history of bariatric surgery: bridging the knowledge gap through a phase 1 study;Journal of Thrombosis and Haemostasis;2024-07

4. Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study;Blood Advances;2024-04-10

5. Assessing the relative contribution of CYP3A-and P-gp-mediated pathways to the overall disposition and drug-drug interaction of dabigatran etexilate using a comprehensive mechanistic physiological-based pharmacokinetic model;Frontiers in Pharmacology;2024-03-07